The rollout reflects the growing clinical value of automated adaptive assessment workflows within routine radiotherapy practice.
Icon’s rollout of ChartCheck Adaptive has progressed steadily since November, with clinical teams reporting positive early experiences as the technology has been incorporated across multiple centres.
The ability to gain consistent, automated insight into daily treatment delivery has supported clinical confidence and positive patient outcomes, while maintaining efficient workflows at scale.
“We have been very pleased with the initial release and use of ChartCheck Adaptive across our Australian centres,” said Trent Aland, Executive Manager, Clinical Care at Icon Group.
“In head and neck cases alone, we are seeing positive early results for our patients which has led to a number being re-planned due to anatomical changes during the course of their treatments.
“Having automated, quantitative insight into daily treatment progression supports confidence in clinical decision making without adding burden to our teams and most importantly, delivering quality patient care.”
Icon has long partnered with Radformation to deploy high quality, patient-centred automation solutions for radiotherapy across its global network.
With ChartCheck Adaptive, Icon adds gold-standard dose recalculation and offline adaptive assessment, helping teams better understand how delivered dose evolves throughout a patient’s course of treatment.
Following the success of the initial release, further releases are planned to commence from March with the software expected to be fully deployed across all Icon Cancer Centre locations globally in the coming months.
As an early adopter of ChartCheck Adaptive and a member of Radformation’s Centre of Excellence, Icon is actively working with Radformation to further enhance the software for wider and more mainstream use.
Radformation has expanded U.S. Food and Drug Administration (FDA) 510(k) clearance of ChartCheck to support its new functionality with ChartCheck Adaptive for clinical use in the United States. ChartCheck Adaptive evaluates daily imaging and treatment data to assess how dose and anatomy change over the course of treatment.
The software automatically delivers this assessment in the background shortly after daily treatment completion, informing clinicians and supporting clinical decision making while preserving the established planning and delivery workflows.
A phased rollout of ChartCheck Adaptive is planned in the United States, alongside continued international deployment in collaboration with leading cancer care providers. This includes IRCCS Sacro Cuore Don Calabria Hospital in Italy, which will be the first centre in Europe to implement ChartCheck Adaptive.
More information about ChartCheck Adaptive
About Radformation
Radformation is committed to improving the lives of clinicians by delivering user-friendly products developed to increase the safety and quality of cancer treatment. Radformation envisions a radiation oncology clinic where staff are equipped with solutions that supplement their expertise and automate time-consuming tasks, leading to better patient care everywhere. Since its founding in 2016, Radformation has grown to serve over 2,400 clinics around the world in over 50 countries with a portfolio of products accelerating all stages of the treatment planning workflow. For more information, visit radformation.com.
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into New Zealand, Asia and the United Kingdom.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.